© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Omid Hamid, MD, and Ryan Sullivan, MD, discuss new updates in uveal melanoma, and an exciting, recently approved agent for treatment of metastatic disease.
July 22nd 2022
Ryan Sullivan, MD, provides an overview of metastatic uveal melanoma, currently available treatment options, and unmet needs in the field.
Dr Omid Hamid explains the mechanism of action of recently approved tebentafusp for mUM, and why HLA testing is necessary for patients being considered for the treatment.
July 29th 2022
Dr Ryan Sullivan details clinical trial data presented at ASCO 2022 on the use of tebentafusp for mUM.
Experts highlight strategies for managing the adverse events of tebentafusp, especially cytokine release syndrome.
August 5th 2022
Omid Hamid, MD, and Ryan Sullivan, MD, discuss what they look forward to in the future of metastatic uveal melanoma treatment.